Napoleone Ferrara

Napoleone Ferrara's AcademicInfluence.com Rankings

Napoleone Ferrara

Biology

#738

World Rank

#1283

Historical Rank

#402

USA Rank

Molecular Biology

#90

World Rank

#93

Historical Rank

#56

USA Rank

biology Degrees

Napoleone Ferrara

Philosophy

#1710

World Rank

#3054

Historical Rank

#665

USA Rank

Logic

#312

World Rank

#629

Historical Rank

#130

USA Rank

philosophy Degrees

Download Badge

Biology
Philosophy

Napoleone Ferrara's Degrees

PhD Molecular Biology University of Catania
Doctorate Medicine University of Catania

Why Is Napoleone Ferrara Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Napoleone Ferrara , is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration , and diabetic retinopathy. At Genentech, he discovered VEGF—and made the first anti-VEGF antibody—which suppresses growth of a variety of tumors. These findings helped lead to development of the first clinically available angiogenesis inhibitor, bevacizumab , which prevents the growth of new blood vessels into a solid tumor and which has become part of standard treatment for a variety of cancers. Ferrara's work led also to the development of ranibizumab , a drug that is highly effective at preventing vision loss in intraocular neovascular disorders.

(See a Problem?)

Napoleone Ferrara's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The biology of VEGF and its receptors (2003) (9029)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. (2004) (8460)
Vascular endothelial growth factor is a secreted angiogenic mitogen. (1989) (5057)
The biology of vascular endothelial growth factor. (1997) (4576)
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene (1996) (3811)
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo (1993) (3698)
Vascular endothelial growth factor: basic science and clinical progress. (2004) (3445)
Angiogenesis as a therapeutic target (2005) (2533)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004) (2410)
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. (1989) (2157)
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. (1992) (2112)
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation (1999) (2004)
Molecular and biological properties of the vascular endothelial growth factor family of proteins. (1992) (1666)
HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation (2003) (1651)
Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway (1998) (1643)
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. (1997) (1632)
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. (1991) (1447)
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover (2002) (1325)
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. (1995) (1282)
Structural characterization and biological functions of fibroblast growth factor. (1987) (1256)
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. (2003) (1224)
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. (1992) (1217)
Molecular and biological properties of vascular endothelial growth factor (1999) (1204)
VEGF and the quest for tumour angiogenesis factors (2002) (1173)
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. (1993) (1168)
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. (1994) (1115)
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. (1994) (1064)
Role of vascular endothelial growth factor in regulation of physiological angiogenesis. (2001) (1041)
Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells* (1998) (1033)
Clinical applications of angiogenic growth factors and their inhibitors (1999) (1032)
VEGF in Signaling and Disease: Beyond Discovery and Development (2019) (991)
Autocrine VEGF Signaling Is Required for Vascular Homeostasis (2007) (988)
HIF-1alpha is essential for myeloid cell-mediated inflammation. (2003) (958)
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. (2005) (935)
VEGF is required for growth and survival in neonatal mice. (1999) (930)
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. (1992) (904)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells (2007) (863)
Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes (1997) (844)
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. (1993) (798)
DEVELOPMENT OF RANIBIZUMAB, AN ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIGEN BINDING FRAGMENT, AS THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (2006) (787)
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. (1995) (739)
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism (2002) (723)
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. (1994) (717)
Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. (2002) (714)
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. (1996) (703)
Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. (1996) (697)
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. (2000) (696)
Vascular endothelial growth factor is essential for corpus luteum angiogenesis (1998) (667)
Targeting the tumour vasculature: insights from physiological angiogenesis (2010) (664)
The vascular endothelial growth factor family of polypeptides (1991) (660)
Ten years of anti-vascular endothelial growth factor therapy (2016) (657)
The Carboxyl-terminal Domain(111165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency (*) (1996) (657)
Developmental and pathological angiogenesis. (2011) (647)
Corneal avascularity is due to soluble VEGF receptor-1 (2006) (647)
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. (1991) (647)
Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 (2003) (647)
Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) (2001) (641)
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. (1996) (626)
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. (2005) (623)
Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. (1995) (622)
Bv8 regulates myeloid-cell-dependent tumour angiogenesis (2007) (585)
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. (1994) (582)
Vascular endothelial growth factor: molecular and biological aspects. (1999) (579)
Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. (1995) (572)
VEGF inhibition and renal thrombotic microangiopathy. (2008) (570)
Vascular endothelial growth factor as a target for anticancer therapy. (2004) (562)
Vascular Endothelial Growth Factor (2009) (561)
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. (2009) (561)
VEGF as a Therapeutic Target in Cancer (2005) (557)
Identification of an angiogenic mitogen selective for endocrine gland endothelium (2001) (557)
Vascular endothelial growth factor and the regulation of angiogenesis. (2000) (550)
Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells (1992) (548)
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes (2010) (515)
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. (1996) (514)
Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors (1996) (513)
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. (2004) (509)
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. (2012) (507)
The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. (2006) (488)
Role of vascular endothelial growth factor in the regulation of angiogenesis. (1999) (487)
VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. (1999) (464)
Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. (1992) (455)
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models (2009) (454)
The Role of Vascular Endothelial Growth Factor in Angiogenesis (2002) (452)
Tumour‐secreted miR‐9 promotes endothelial cell migration and angiogenesis by activating the JAK‐STAT pathway (2012) (411)
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. (1998) (407)
The hypoxic response of tumors is dependent on their microenvironment. (2003) (404)
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. (2002) (398)
CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. (2012) (394)
Angiogenesis and bone growth. (2000) (389)
VEGF: an update on biological and therapeutic aspects. (2000) (389)
An interleukin-17–mediated paracrine network promotes tumor resistance to anti-angiogenic therapy (2013) (384)
Role of VEGF-A in Vascularization of Pancreatic Islets (2003) (381)
VEGFA is necessary for chondrocyte survival during bone development (2004) (380)
Consensus guidelines for the use and interpretation of angiogenesis assays (2018) (370)
The molecular basis of vascular lumen formation in the developing mouse aorta. (2009) (362)
Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. (2001) (354)
Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF* (2006) (352)
Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal Administration (1999) (351)
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function (2001) (350)
Vascular endothelial growth factor a in intraocular vascular disease. (2013) (341)
Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development (2010) (337)
The role of vascular endothelial growth factor in pathological angiogenesis (2004) (322)
The role of VEGF in the regulation of physiological and pathological angiogenesis. (2005) (321)
The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. (1992) (321)
Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. (2005) (318)
VEGF-A: a critical regulator of blood vessel growth. (2009) (318)
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. (1996) (316)
Role of vascular endothelial growth factor in the regulation of angiogenesis (1999) (314)
VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis (2004) (312)
Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. (2012) (304)
Induction of Vascular Endothelial Growth Factor by Insulin-like Growth Factor 1 in Colorectal Carcinoma* (1996) (301)
Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective (2006) (301)
Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. (1996) (300)
Pathways mediating VEGF-independent tumor angiogenesis. (2010) (298)
Vascular endothelial growth factor is expressed in rat corpus luteum. (1990) (297)
Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells (*) (1995) (289)
Vascular endothelial growth factor signaling pathways: therapeutic perspective. (2008) (287)
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression (2008) (276)
Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. (1992) (271)
Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. (1993) (268)
Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. (2003) (265)
Neutralizing anti‐vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo (1998) (262)
Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells (2011) (260)
Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. (1994) (258)
Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. (2000) (257)
Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. (1996) (255)
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. (2001) (254)
Hypoxic Induction of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen (1995) (251)
Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells* (1998) (248)
Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. (1994) (242)
The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis (2016) (238)
Targeting VEGF-A to treat cancer and age-related macular degeneration. (2007) (236)
Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback (2005) (236)
Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro * (1998) (233)
Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. (1996) (230)
Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. (2004) (226)
Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. (2006) (226)
Dll4 and Notch signalling couples sprouting angiogenesis and artery formation (2017) (220)
Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. (1997) (218)
Binding to the Extracellular Matrix and Proteolytic Processing: Two Key Mechanisms Regulating Vascular Endothelial Growth Factor Action (2010) (218)
The second immunoglobulin‐like domain of the VEGF tyrosine kinase receptor Flt‐1 determines ligand binding and may initiate a signal transduction cascade. (1996) (217)
The role of VEGF in normal and neoplastic hematopoiesis (2002) (215)
Bovine brain astrocytes express basic fibroblast growth factor, a neurotropic and angiogenic mitogen (1988) (215)
Local guidance of emerging vessel sprouts requires soluble Flt-1. (2009) (214)
Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. (1998) (214)
In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of action. (1994) (213)
Angiogenic inhibitors: a new therapeutic strategy in oncology (2005) (212)
The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells (2003) (211)
Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma (2013) (209)
The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. (1991) (209)
Contribution of Vascular Endothelial Growth Factor in the Neovascularization Process during the Pathogenesis of Herpetic Stromal Keratitis (2001) (208)
Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. (1999) (207)
Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. (1995) (204)
Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. (2000) (200)
Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. (2003) (199)
Pituitary follicular cells produce basic fibroblast growth factor. (1987) (199)
VEGF inhibition: insights from preclinical and clinical studies (2008) (194)
Angiogenesis-Dependent and Independent Phases of Intimal Hyperplasia (2004) (188)
A repressor sequence in the juxtamembrane domain of Flt‐1 (VEGFR‐1) constitutively inhibits vascular endothelial growth factor‐dependent phosphatidylinositol 3′‐kinase activation and endothelial cell migration (2000) (188)
ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3 and Induces Blood Vessel Formation in Vivo * (2002) (186)
Bovine granulosa cells produce basic fibroblast growth factor. (1987) (181)
Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor (2004) (181)
Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. (2004) (172)
Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. (1993) (172)
A direct and melanopsin-dependent fetal light response regulates mouse eye development (2013) (171)
Capillary regression in vascular endothelial growth factor-deficient skeletal muscle. (2004) (171)
Vascular endothelial growth factor, a specific regulator of angiogenesis (1996) (171)
Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy (2010) (169)
Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. (1996) (168)
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. 1989. (2012) (168)
Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. (2002) (167)
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. (2008) (166)
Interaction between bevacizumab and murine VEGF-A: a reassessment. (2008) (166)
PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth (2010) (164)
Comparative Analysis of Vascular Endothelial Growth Factor Receptors on Retinal and Aortic Vascular Endothelial Cells (1995) (162)
Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb. (1994) (160)
Role of myeloid cells in tumor angiogenesis and growth. (2008) (156)
Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. (2010) (155)
Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. (1996) (154)
Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis (2010) (153)
Antiangiogenic Therapy for Cancer: An Update (2007) (152)
Recovery of disturbed endothelium-dependent flow in the collateral-perfused rabbit ischemic hindlimb after administration of vascular endothelial growth factor. (1995) (151)
Aortic smooth muscle cells express and secrete vascular endothelial growth factor. (1991) (149)
Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1 (2017) (144)
Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging (2009) (143)
Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. (1996) (142)
Soluble FLT1 Binds Lipid Microdomains in Podocytes to Control Cell Morphology and Glomerular Barrier Function (2012) (140)
Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. (1995) (139)
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. (2009) (136)
Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. (2007) (133)
Endothelium-microenvironment interactions in the developing embryo and in the adult. (2007) (133)
VEGF-A regulated by progesterone governs uterine angiogenesis and vascular remodelling during pregnancy (2013) (130)
Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. (2007) (128)
Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. (2008) (127)
Vascular endothelial growth factor. (1996) (127)
VEGF regulates cell behavior during vasculogenesis. (2000) (125)
Astrocyte-Derived Vascular Endothelial Growth Factor Stabilizes Vessels in the Developing Retinal Vasculature (2010) (122)
Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: identification as leukemia inhibitory factor. (1992) (122)
ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. (2002) (121)
Tumor-Driven Paracrine Platelet-Derived Growth Factor Receptor α Signaling Is a Key Determinant of Stromal Cell Recruitment in a Model of Human Lung Carcinoma (2006) (120)
In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells. (1994) (117)
Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. (1995) (117)
Growth factors: Formation of endothelial cell networks (2000) (115)
Endocrine gland–derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis (2002) (115)
The heart endocardium is derived from vascular endothelial progenitors (2011) (114)
Basic fibroblast growth factor: expression in cultured bovine vascular smooth muscle cells. (1988) (110)
Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity (2016) (107)
Characterization of Endocrine Gland-derived Vascular Endothelial Growth Factor Signaling in Adrenal Cortex Capillary Endothelial Cells* (2002) (107)
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu (2012) (107)
S1P1 inhibits sprouting angiogenesis during vascular development (2012) (106)
Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. (1990) (106)
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies (2007) (105)
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment (2013) (105)
Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells. (1991) (105)
Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy (2011) (101)
The Regulation of Blood Vessel Growth by Vascular Endothelial Growth Factor (1995) (101)
Vascular endothelial growth factor attenuates myocardial ischemia-reperfusion injury. (1997) (101)
Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation (2010) (101)
Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. (1998) (100)
Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A 1 in Vascular Endothelial Cells * (1998) (100)
Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. (1995) (99)
Vascular endothelial growth factor. (1993) (97)
The forming limb skeleton serves as a signaling center for limb vasculature patterning via regulation of Vegf (2009) (94)
Comparing protein VEGF inhibitors: In vitro biological studies. (2011) (91)
Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity (2016) (89)
Vascular endothelial growth factor augments muscle blood flow and function in a rabbit model of chronic hindlimb ischemia. (1996) (87)
Vascular endothelial growth factor. The trigger for neovascularization in the eye. (1995) (85)
Vascular endothelial growth factor: basic biology and clinical implications. (1997) (84)
Basic fibroblast growth factor: expression in cultured cells derived from corneal endothelium and lens epithelium. (1988) (84)
Differential drug class‐specific metastatic effects following treatment with a panel of angiogenesis inhibitors (2012) (83)
A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain (2015) (83)
Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans (1999) (82)
Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models (2012) (79)
Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. (2014) (78)
A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. (2010) (77)
EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors. (2004) (73)
Characterization and Regulation of Bv8 in Human Blood Cells (2009) (73)
Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1 (2013) (72)
Vascular endothelial growth factor co-ordinates proper development of lung epithelium and vasculature (2005) (71)
Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice (2007) (70)
Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. (2008) (69)
Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis. (2004) (68)
Mapping the Charged Residues in the Second Immunoglobulin-like Domain of the Vascular Endothelial Growth Factor/Placenta Growth Factor Receptor Flt-1 Required for Binding and Structural Stability* (1998) (67)
VEGF and Intraocular Neovascularization: From Discovery to Therapy (2016) (67)
Induction of Bv8 Expression by Granulocyte Colony-stimulating Factor in CD11b+Gr1+ Cells (2012) (66)
Hepatocyte growth factor. A cytokine mediating endothelial migration in inflammatory arthritis. (1996) (65)
VEGF regulates remodeling during permanent anatomic closure of the ductus arteriosus. (2002) (64)
Corticotropin regulates vascular endothelial growth factor expression in human fetal adrenal cortical cells. (1998) (61)
Antiangiogenesis to treat cancer and intraocular neovascular disorders (2007) (61)
Phosphoproteomic Analysis Implicates the mTORC2-FoxO1 Axis in VEGF Signaling and Feedback Activation of Receptor Tyrosine Kinases (2013) (60)
Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. (2000) (58)
Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. (2003) (55)
Blocking Vascular Endothelial Growth Factor-A Inhibits the Growth of Pituitary Adenomas and Lowers Serum Prolactin Level in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (2008) (55)
EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function. (2003) (54)
Crim1 maintains retinal vascular stability during development by regulating endothelial cell Vegfa autocrine signaling (2014) (54)
Evidence for Pro-angiogenic Functions of VEGF-Ax (2016) (53)
Quantification of viable tumor microvascular characteristics by multispectral analysis (2008) (51)
Macrophage Wnt-Calcineurin-Flt1 signaling regulates mouse wound angiogenesis and repair. (2013) (51)
Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies (2013) (51)
Missing link in angiogenesis (1995) (50)
The Prokineticins: Neuromodulators and Mediators of Inflammation and Myeloid Cell-Dependent Angiogenesis. (2018) (50)
Neutralizing VEGF bioactivity with a soluble chimeric VEGF‐receptor protein flt(1‐3)IgG inhibits testosterone‐stimulated prostate growth in castrated mice (2004) (49)
Crystallization of the receptor binding domain of vascular endothelial growth factor (1996) (46)
Fibroblast growth factor and the control of pituitary and gonad development and function. (1989) (45)
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas (2020) (45)
Substantially attenuated hemodynamic responses to Escherichia coli-derived vascular endothelial growth factor given by intravenous infusion compared with bolus injection. (1998) (45)
EG-VEGF and the concept of tissue-specific angiogenic growth factors. (2002) (44)
Vascular Endothelial Growth Factor: Basic Biology and Clinical Applications (2009) (43)
Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. (2006) (42)
Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-CΔNΔC- and VEGF-A-induced angiogenesis in vitro (2003) (42)
Metastatic growth instructed by neutrophil-derived transferrin (2018) (41)
Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis. (1993) (41)
Loss of vascular endothelial growth factor A (VEGFA) isoforms in the testes of male mice causes subfertility, reduces sperm numbers, and alters expression of genes that regulate undifferentiated spermatogonia. (2013) (41)
Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability. (2010) (41)
Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. (2016) (37)
OncogenicrasFails to Restore anin VivoTumorigenic Phenotype in Embryonic Stem Cells Lacking Vascular Endothelial Growth Factor (VEGF) (1999) (37)
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factoryvascular permeability factor antibody (angiogenesisyvascular obstruction) (1996) (36)
The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation. (1996) (35)
Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL12 (2013) (35)
Decrease in Tumor Apparent Permeability‐Surface Area Product to a MRI Macromolecular Contrast Medium Following Angiogenesis Inhibition with Correlations to Cytotoxic Drug Accumulation (2004) (35)
Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer (2020) (33)
Platelet-derived growth factor C promotes revascularization in ischemic limbs of diabetic mice. (2014) (32)
Transport epithelial characteristics of cultured bovine pituitary follicular cells. (1987) (32)
Interleukin-22 promotes tumor angiogenesis (2018) (32)
Comparative effects of estrogens and prolactin on nigral and striatal GAD activity (1982) (31)
Dobutamine stress cine‐MRI of cardiac function in the hearts of adult cardiomyocyte‐specific VEGF knockout mice (2001) (31)
The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor (2004) (31)
From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. (2011) (31)
Stromal Cell-Derived Factor-1/CXCL12 Contributes to MMTV-Wnt1 Tumor Growth Involving Gr1+CD11b+ Cells (2010) (29)
Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response. (2013) (28)
Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). (2003) (28)
EG‐VEGF: A Novel Mediator of Endocrine‐Specific Angiogenesis, Endothelial Phenotype, and Function (2004) (25)
Influence of sex steroids and prolactin on haloperidol-induced catalepsy (1983) (25)
Vegf regulates embryonic erythroid development through Gata1 modulation. (2010) (24)
Imaging tumor angiogenesis. (2006) (24)
The function of VEGF-A in lens development: formation of the hyaloid capillary network and protection against transient nuclear cataracts. (2009) (24)
Multiple effects of angiopoietin-2 blockade on tumors. (2011) (23)
Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF). (1999) (22)
Loss of Vascular Endothelial Growth Factor A (VEGFA) Isoforms in Granulosa Cells Using pDmrt-1-Cre or Amhr2-Cre Reduces Fertility by Arresting Follicular Development and by Reducing Litter Size in Female Mice (2015) (21)
VEGF and its receptors (2004) (20)
Endothelial cells regulate neural crest and second heart field morphogenesis (2014) (19)
Inhibition of vascular endothelial cell growth factor suppresses the in vivo growth of human prostate tumors. (1997) (18)
Leukemia inhibitory factor expression in human carotid plaques: possible mechanism for inhibition of large vessel endothelial regrowth. (1993) (17)
Molecular Characterization and Distribution of Vascular Endothelial Growth Factor (1991) (17)
Inhibition of protein glycosylation is a novel pro-angiogenic strategy that acts via activation of stress pathways (2020) (17)
Inhibition of protein kinase C enhances angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cells (2015) (17)
Vascular patterning regulates interdigital cell death by a ROS-mediated mechanism (2015) (16)
ENDOCRINE GLAND VASCULAR ENDOTHELIAL GROWTH FACTOR (EG-VEGF) AND THE HYPOTHESIS OF TISSUE-SPECIFIC REGULATION OF ANGIOGENESIS (2002) (15)
Inhibiting the Response to VEGF in Diabetes (2014) (15)
Natural killer cells, adhesion and tumor angiogenesis (1996) (14)
Culture and characterization of follicular cells of the bovine anterior pituitary and pars tuberalis. (1986) (14)
Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro. (2003) (14)
The role of EG-VEGF in the regulation of angiogenesis in endocrine glands. (2002) (14)
Paracrine VEGF/VE-Cadherin Action on Ovarian Cancer Permeability (2006) (13)
Iron Metabolism in the Tumor Microenvironment: Contributions of Innate Immune Cells (2021) (13)
Vascular endothelial growth factor: pathophysiology and clinical implications (2006) (13)
Angiogenesis : From Basic Science to Clinical Applications (2006) (13)
Regulation of ion transport in hypophysial pars intermedia follicular cell monolayers. (1988) (12)
Outer retinal tubulations response to anti-VEGF treatment (2015) (12)
Targeting the Tumor Microenvironment With Src Kinase Inhibition (2010) (10)
Induction of Bv 8 expression by granulocyte-colony stimulating factor in CD 11 b + Gr 1 + cells : Key role of Stat 3 signaling (2012) (9)
The Role of the VEGF Signaling Pathway in Tumor Angiogenesis (2019) (9)
Vascular targeting via caveolae (2007) (8)
Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders (2021) (8)
Erratum: HIF-1α is essential for myeloid cell-mediated inflammation (Cell 112:5 (648)) (2003) (8)
Vascular Endothelial Growth Factor Molecular and Biological Aspects (1999) (7)
Microvascular Density as a Predictive Biomarker for Bevacizumab Survival Benefit in Ovarian Cancer: Back to First Principles? (2017) (7)
History of Discovery Vascular Endothelial Growth Factor (2009) (7)
LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy (2021) (6)
VEGF modulates synaptic activity in the developing spinal cord (2014) (6)
Vascular heterogeneity: VEGF receptors make blood vessels special (2022) (4)
Revascularization achieved by therapeutic angiogenesis is associated with improvement of tissue perfusion (1996) (3)
Tumor-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway (2012) (3)
Anti-angiogenic drugs to treat human disease: an interview with Napoleone Ferrara by Kristin H. Kain. (2009) (3)
Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors. (2008) (3)
The Biology of Vascular Endothelial Growth Factor, a Specific Regulator of Angiogenesis (1997) (3)
Targeting the Tumor Microenvironment With Src (2010) (2)
Role of Myeloid Cells in Tumor Angiogenesis (2012) (2)
Abstracts of the ECTS congress 2017 (2017) (2)
The Role of VEGF in Tumor Angiogenesis (2004) (2)
Overview and Clinical Applications of VEGF-A (2008) (2)
Naturally occurring combinations of receptors from single cell transcriptomics in endothelial cells (2021) (2)
The VEGF Receptor Family (2015) (2)
Napoleone Ferrara discusses Avastin and the future of anti-angiogenesis therapy. Interview by Ulrike Knies-Bamforth and Christopher Watson. (2005) (2)
Bone Research Society, Annual Meeting 2017 Proceedings (2018) (1)
The Regulation of Normal and Pathological Angiogenesis by Vascular Endothelial Growth Factor (1995) (1)
CHAPTER 34 – Pathophysiology of vascular endothelial growth factor and other angiogenic molecules (2010) (1)
Interleukin-22 promotes tumor angiogenesis (2018) (1)
PROTEIN KINASE C-α INHIBITS ANGIOGENESIS INDUCED BY PLATELET-DERIVED GROWTH FACTOR C IN HYPERGLYCEMIC ENDOTHELIAL CELLS (2015) (1)
Remembering Jean Plouet, Pioneer of Angiogenesis Research in France and Co-Discoverer of Vascular Endothelial Growth Factor (2008) (1)
A CRUCIAL ROLE OF PDGF–C IN IMPAIRED ANGIOGENESIS OF DIABETES (2013) (1)
Vascular Endothelial Growth Factor: A Key Regulator of Physiologic Angiogenesis (2001) (1)
1012-103 Restoration of Endothelial Function in Hypercholesterolemic Rabbit by Intermittent Administration of Vascular Endothelial Growth Factor (1995) (1)
A conversation with Napoleone Ferrara. (2014) (1)
Endothelial Cell Diversity: the Many Facets of the Crystal. (2022) (1)
Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer (2022) (1)
Prolactin influences sexual behavior during aging. (1985) (1)
Commentary on "Humanization of an Anti-VEGF Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders". (2016) (1)
Vascular Bed-Specific Signaling and Angiogenesis (2005) (1)
Eg-vegf nucleic acids and polypeptides and methods for their use (2001) (1)
Sertoli and Germ Cell Vascular Endothelial Growth Factor A (VEGFA) Loss Using pDMRT-1 Cre Affects Testis Size and Reduces Spermatogenesis Potentially Through Altering Genes Regulating the Spermatogonial Stem Cell Niche. (2011) (1)
Inhibitors of angiopoitin-like 4 protein, combinations and uses thereof (2005) (0)
膵β細胞におけるVEGF-Aの役割(平成16年度順天堂大学老人性疾患病態・治療研究センター研究発表会抄録) (2005) (0)
Variants of the growth factor of vascular endothelial cells, their use and methods for their production (1996) (0)
Abstract 228: Distinct Roles of PDGF-C and VEGF in Impaired Angiogenesis of Diabetes and Its Implication in Therapeutic Angiogenesis (2013) (0)
Vascular endothelial growth factor:A critical regulator of angiogenesis (2006) (0)
Endothelial cell specific gene expression changes in Oxygen Induced Retinopathy (OIR) (2018) (0)
Blockade of VEGF-A prevents mobilization and recruitment of endothelial progenitor cells (EPCs) to the tumor vasculature (2005) (0)
Erratum to: A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain [Cancer Cell. 2015 27(6):780-96.] DOI: 10.1016/j.ccell.2015.04.017 (2015) (0)
Targeting angiogenesis in oncology, ophthalmology and beyond. (2023) (0)
New inhibitors of the activity of factor vascular endothelial growth, their uses and processes for their production. (1997) (0)
Vascular Endothelial Growth Factor A (VEGFA) Isoform Loss Reduces Ovarian Size, Estrogen Concentrations, mRNA Abundance of Genes Critical to Follicular Development and Oocyte Growth Resulting in Subfertility. (2011) (0)
TARGETING VEGF: FROM BENCH TO BEDSIDE (2004) (0)
RPE–Produced VEGF in Choriocapillaris Function (2006) (0)
Cancer Therapy : Preclinical Development and Preclinical Characterization of a Humanized Antibody Targeting CXCL 12 (2013) (0)
Pericytes regulate VEGF-induced endothelial sprouting through VEGFR1 (2017) (0)
Antagnositas growth factor of vascular endothelial cells. (1996) (0)
Use of the antagonists of vascular endothelial cell growth factor (1992) (0)
Vegf and bmp1 homological polypeptides. (1999) (0)
Role of the Retinal Müller Cells in Diabetic Retinopathy (2007) (0)
Subject Index Vol. 106, 2001 (2002) (0)
Vascular endothelcellevækstfaktorantagonister and uses thereof (1999) (0)
Soluble Vascular Endothelial Growth Factor Receptor 1 (sflt-1) is Essential for Subretinal Vascular Zoning (2010) (0)
Title Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor (2014) (0)
Use of the antagonist of leukemia inhibitory factor (1996) (0)
Adventitial angiogenesis drives neointima formation (2003) (0)
Anticorps anti-tgf-beta humanises (2005) (0)
Vascular endothel cell growth factor variants with antagonistic effect (1997) (0)
Growth factor variants of vascular endothelial cells, their uses and procedures. (1996) (0)
Protein inhibitors angiopoietin-like 4, combinations and their use. (2005) (0)
Inducible gene-targeting reveals critical roles for VEGFR-1 and VEGFR-2 during early postnatal development in the mouse (2005) (0)
Variants of the growth factor for vascular endothelial cells with antagonistic properties (1997) (0)
Lens VEGF-A Contributes to the Formation of the Fetal Vasculature, but Is Not Necessary for Lens Development (2003) (0)
Growth factor antagonists of vascular endothelial cells vegf. (1992) (0)
VEGF and BMP1-homologous polypeptides (1999) (0)
Antagonists endothelial growth factor and its uses. (1999) (0)
pDmrt1-Cre;Vegfa -/- and control ovary histology. (2015) (0)
The role of the EG-VEGF family in the regulation of angiogenesis in endocrine glands (2003) (0)
Role of Myeloid and Other Stromal Cell Types in Tumor Angiogenesis. (2009) (0)
Use of antigonists of the vegf cellular growth factor. (1992) (0)
Antagonist of vascular endothelial growth factor (1996) (0)
Abstract 1475: Blockade of IL17-GCSF-Bv8 inflammation axis ameliorate resistant to anti-angiogenic therapy for colon cancer (2020) (0)
Homologous VEGF and BMP1 polypeptides (1999) (0)
Use of the antagonist leukemia-inhibitor-factor and endothelin (1996) (0)
Using antagonists vascular endothelial growth factor. (1992) (0)
Title Dll 4 and Notch signalling couples sprouting angiogenesis and artery formation (2017) (0)
Antagonist of vascular endothelial cell growth factors and their application (1999) (0)
TITLE : Comberons from single cell transcriptomics in endothelial cells (2021) (0)
polypeptide to vegf and BMP1 homologous (1999) (0)
Abstract IA17: Targeting placental growth factor/ neuropilin-1 pathway inhibits growth and spread of medulloblastoma (2014) (0)
Inhibition of tumor metastasis using anti-G-CSF (2010) (0)
related vascular endothelial cell growth factor antagonists (1995) (0)
Use of anti-VEGF for the treatment of cancer antibodies. (1992) (0)
Light as a regulator of vascular regression (2011) (0)
Variants of vascular endothelial cell growth factor, as well as applications of these processes for the preparation thereof (1996) (0)
Variants cell growth factor of vascular endothelium having antagonistic properties. (1997) (0)
Contents Vol. 106, 2001 (2002) (0)
Homologous polypeptide with vefg and bmp1 (2008) (0)
Science Signaling Podcast: 16 April 2013 (2013) (0)
A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain (2015) (0)
Molecular Heterogeneity of VEGF–A in the Vitreous of Patients with Proliferative Diabetic Retinopathy (2006) (0)
Use of antagonists of cell growth factor VEGF (1992) (0)
Sertoli and Granulosa Cell-Specific Vascular Endothelial Growth Factor (VEGF) Loss Using pDMRT-1 Cre Alters Gonadal Morphogenesis and Function. (2010) (0)
Author response: Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1 (2013) (0)
Antagonists of vascular growth factors endotheliales cells. (1996) (0)
Angiopoietin-like 4 protein inhibitor combinations and their use (2005) (0)
Novel inhibitors of the activity of the growth factor for vascular endothelial cells (vegf), their uses and processes for their production (1997) (0)
The production of vascular endothelial cell growth factor, as well as DNA coding for the (1990) (0)
Culture of vascular endothelial growth factor of dns and encoding it (1990) (0)
2 Vascular Endothelial Growth Factor : Basic Biology and Clinical Applications (2020) (0)
PLACENTAL GROWTH FACTOR/NEUROPILIN 1 SIGNALING IS A THERAPEUTIC TARGET IN PEDIATRIC MEDULLOBLASTOMA (2013) (0)
Variants of vascular endothelzellwachsumsfaktors with antagonistic effect (1997) (0)
Use of anti-vegf for tratammiento of cancer antibodies. (1992) (0)
modulation Vegf regulates embryonic erythroid development through Gata1 (2013) (0)
Down syndrome critical region proteinl (DSCR1), a novel VEGF target gene that regulates expression of COX-2 on activated endothelial cells (2005) (0)
Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor (2008) (0)
We employed two independent approaches to inactivate the angiogenic protein VEGF in newborn mice: inducible, Cre- loxP- mediated gene targeting, or administration of mFlt(1- 3)-IgG, a soluble VEGF receptor chimeric protein. Partial inhibition of VEGF achieved by inducible gene targeting (1999) (0)
Anti-angiogenic therapy: New insights (2013) (0)
Model of Lower Limb Vascular Insufficiency (2007) (0)
BlockingVascular Endothelial Growth Factor-A Inhibits the Growth of PituitaryAdenomas and Lowers Serum Prolactin Level in a MouseModel of Multiple Endocrine NeoplasiaType 1 (2007) (0)
Consensus guidelines for the use and interpretation of angiogenesis assays (2018) (0)
Vascular tortuosity quantification as an outcome metric of the oxygen-induced retinopathy model of ischemic retinopathy (2022) (0)
Homologous polypeptide to Vegf and bmp1 (2013) (0)
An endothelial cell growth, the isolation and expression (1990) (0)
Sex difference in plasma prolactin response to low dose of naloxone in humans (1980) (0)
ADUVANT AND NEOADUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMIORS (2017) (0)
Homologues tie ligands. (1998) (0)
Homologue NL3 ligand receptor kinase trirosina tie. (1998) (0)
Homologous NL6 the Tie receptor tyrosine kinase ligands (1998) (0)
Homologues du ligand 'tie' du type tyrosine kinase receptrice (1998) (0)
Secreted polypeptides and nucleic acids encoding (1999) (0)
A Message from the New Editor-in-Chief (2014) (0)
Ligand homologues "tie" receptor tyrosine kinase. (1998) (0)
VEGF-specific antagonists of adjuvant and neoadjuvant therapy and treatment of tumors of the early stage (2007) (0)
Introduction by the Guest Editors: Bevacizumab. (2018) (0)
Nucleic acids of eg-vegf and polypeptides and methods of use. (2001) (0)
Homologues of the tie-rezeptortyrosinekinase ligand (1998) (0)
Homologous of tie receptortyrosine kinase liganden (1998) (0)
Secreted and transmembrane polypeptides and nucleic acids to their codes (2000) (0)
Anti-Vascular Endothelial Growth Factor Therapy and Renal Thrombotic Microangiopathy (2017) (0)

This paper list is powered by the following services:

Other Resources About Napoleone Ferrara

en.wikipedia.org

What Schools Are Affiliated With Napoleone Ferrara?

Napoleone Ferrara is affiliated with the following schools:

Napoleone Ferrara's Academic­Influence.com Rankings

Napoleone Ferrara's Degrees

Why Is Napoleone Ferrara Influential?

Napoleone Ferrara's Published Works

Published Works

Other Resources About Napoleone Ferrara

What Schools Are Affiliated With Napoleone Ferrara?

Napoleone Ferrara's AcademicInfluence.com Rankings